These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 13834524)
1. [Morphological modifications of the characteristic pathological cells of the Oberling, Guerin and Guerin myeloma in rats treated with bis(beta-chloroethyl)-p-aminophenyl alanine]. STEVE BOCCIARELLI D; VIOLANTE A Rend Ist Sup Sanit; 1960; 23():111-21. PubMed ID: 13834524 [No Abstract] [Full Text] [Related]
2. [Experimental transmissible neuraxitis in the rabbit in relation to the etiological complex of the Oberling-Guerin-Guerin rat myeloma]. CONSOLI G; RICCIARDI S; CORAGGIO F; ALTUCCI P; TALARICO L; RICCARDI C Riv Ist Sieroter Ital; 1959; 34():280-98. PubMed ID: 13849436 [No Abstract] [Full Text] [Related]
3. [Experimental anatomo-pathological study of the action of the toxohormone extracted from the T 58 myelosarcoma of Oberling and Guerin on the lymphoid ganglia of the rat]. BIRABEN J; DELMON G C R Seances Soc Biol Fil; 1960; 154():594-6. PubMed ID: 13800819 [No Abstract] [Full Text] [Related]
4. [Repeated remissions in a case of beta-plasmocytoma; variations in the blood protein picture during p-bis(2-chloroethyl)-aminophenylalanine therapy]. CASTELLANO M; CATTANEO C Minerva Med; 1959 Jul; 50():2365-9. PubMed ID: 13808275 [No Abstract] [Full Text] [Related]
5. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). BERGSAGEL DE; SPRAGUE CC; AUSTIN C; GRIFFITH KM Cancer Chemother Rep; 1962 Aug; 21():87-99. PubMed ID: 13867794 [No Abstract] [Full Text] [Related]
14. [Study in vivo of polyvinylpyrrolidone-I-131 fixation in Oberling-Guerin myeloma]. BECCHINI MF; DE RENZI G; LAMARCHE V; GIORDANI R Boll Soc Ital Biol Sper; 1962 Dec; 38():1267-8. PubMed ID: 13970033 [No Abstract] [Full Text] [Related]
15. [Effect of a peptide complex of m-di-(2-chloroethyl)amino-L-phenylalanine on some immunological reactions]. Nanni G; Marinari UM Boll Ist Sieroter Milan; 1971; 50(4):334-40. PubMed ID: 5163504 [No Abstract] [Full Text] [Related]
16. Identification of a new bis-amino acid glycoside selectively toxic to multiple myeloma cells. Cheng CY; Feng YY; Zang Y; Li J; He XP; Chen GR Carbohydr Res; 2014 Jul; 394():39-42. PubMed ID: 24972313 [TBL] [Abstract][Full Text] [Related]
17. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells. Stefka AT; Park JH; Matsuo Y; Chung S; Nakamura Y; Jakubowiak AJ; Rosebeck S Blood Cancer J; 2016 Aug; 6(8):e460. PubMed ID: 27540718 [No Abstract] [Full Text] [Related]
18. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. VI. Metasarcolysin. AUSTIN C; BERGSAGEL DE; SPRAGUE CC Cancer Chemother Rep; 1962 Aug; 21():107-12. PubMed ID: 13863325 [No Abstract] [Full Text] [Related]
19. [Experience with the use of sarcolysin in multiple myeloma]. ALEKSEEV GA; PETROV KIa Probl Gematol Pereliv Krovi; 1961 Dec; 6():3-10. PubMed ID: 13860267 [No Abstract] [Full Text] [Related]
20. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. III. AB-100 (NSC-37095). BROWN CL; BERGSAGEL DE; LEVIN WC Cancer Chemother Rep; 1962 Aug; 21():81-5. PubMed ID: 13873596 [No Abstract] [Full Text] [Related] [Next] [New Search]